Role of Curcumin in Paclitaxel Induced PN

Trial Title: Role of Curcumin in Paclitaxel Induced PN

NCT ID: NCT05966441

Condition: Chemotherapy-induced Peripheral Neuropathy

Conditions: Official terms:
Peripheral Nervous System Diseases
Curcumin
Paclitaxel

Conditions: Keywords:
Paclitaxel
Curcumin
Breast Cancer

Study type: Interventional

Study phase: Phase 2

Overall status: Not yet recruiting

Study design:

Allocation: Randomized

Intervention model: Parallel Assignment

Intervention model description: - Details of the research steps that the subscriber will be exposed to: - Base line evaluation then alignment in either intervention or control group either for taking the interventional drug or standard of care in control group. - Blood samples will be collected at baseline. - Patient will be given a weekly supply of the medication and will be asked to take his prescribed dose daily. - Every week all patients will be asked about their symptoms and if they experience any adverse drug reaction. - Patients will receive the interventional drug until the last paclitaxel dose will be taken. - After 3 months, another full clinical examination and blood sample will be obtained.

Primary purpose: Prevention

Masking: None (Open Label)

Intervention:

Intervention type: Dietary Supplement
Intervention name: Curcumin
Description: The safety of curcumin has been widely demonstrated, and curcumin has a variety of potential pharmaceutical applications. Curcumin exhibits antioxidant, anti-inflammatory and anticancer properties and has been described as neuroprotective against neurological disorders. Many of curcumin's pharmacological benefits arise from its antioxidant or anti-inflammatory properties. Curcumin appears to have significant potential for treatment of diseases that result from oxidative stress. Curcumin is provided in soft gelatin capsules each capsule contains 1 g of curcumin and patient is asked to take 2 capsules daily
Arm group label: Control group
Arm group label: Experimental group

Intervention type: Drug
Intervention name: Paclitaxel
Description: Paclitaxel (PTX), the most widely used anticancer drug, is applied for the treatment of various types of malignant diseases. Mechanisms of PTX action represent several ways in which PTX affects cellular processes resulting in programmed cell death. PTX is frequently used as the first-line treatment drug in breast cancer Paclitaxel dose in adjuvant therapy after doxorubicin and cyclophosphamide every 3 weeks 175mg/m2 IV or Weekly 80 mg/m2 IV.. Paclitaxel dose in neoadjuvant therapy every 3 weeks 175 mg/m2 IV.
Arm group label: Control group
Arm group label: Experimental group

Summary: Paclitaxel induced peripheral neuropathy is the most common and serious side effect associated with Paclitaxel treatment in breast cancer patients receiving Paclitaxel. The efficacy of antioxidant molecules as neuroprotective strategies to preventing the development of peripheral neuropathy has been investigated in preclinical and clinical studies. Vitamin E and Glutathione have been explored as adjuvant therapies to preventing taxane-induced peripheral neuropathy. Other tested neuroprotective treatments with limited success include amifostine, glutamine and acetyl l-carnitine. Curcumin's antioxidant capacity is similar to other potent antioxidants, such as trolox (a vitamin E analog). Curcumin inhibits lipid peroxidation in different tissues, regulates intracellular levels of antioxidant enzymes (e.g., catalase, glutathione peroxidase and superoxide dismutase) and is an effective intracellular reactive oxygen species (ROS) scavenger. The investigators are going to investigate the neuroprotective effect of Curcumin against Paclitaxel induced peripheral neuropathy.

Detailed description: The work is a prospective, randomized, open label controlled study. A total of 90 breast cancer female patients will be enrolled in the study. Eligible patients will simply be randomized using random allocation generator, after the end of anthracycline adjuvant therapy to one of two groups, Group I: will receive paclitaxel regimen plus 2g of curcumin Group II: will receive paclitaxel regimen only. The cases involved in the study will be recruited from Ain Shams Teaching Hospital. All patients presenting to the department were assessed for eligibility according to certain inclusion and exclusion criteria. Details of the research steps that the subscriber will be exposed to: - Base line evaluation then alignment in either intervention or control group either for taking the interventional drug or standard of care in control group. - Blood samples will be collected at baseline. - Patient will be given a weekly supply of the medication and will be asked to take his prescribed dose daily. - Every week all patients will be asked about their symptoms and if they experience any adverse drug reaction. - Patients will receive the interventional drug until the last paclitaxel dose will be taken. - After 3 months, another full clinical examination and blood sample will be obtained.

Criteria for eligibility:
Criteria:
Inclusion Criteria: - Clinical diagnosis of early stage breast cancer with age > 18 years. - Performance status of the patients based on Eastern Cooperative Oncology Group (ECOG) from 0 to 2. - Patients must receive paclitaxel 80 mg/m2 weekly or 175 mg/m2 every 3 weeks for 12 weeks. - Patients clinical parameters should be (ANC ≥ 1500/mm3). Platelet count 100,000/mm3) (serum total bilirubin < 1.5 mg/dl) and (creatinine < 1.5 mg/dl). Exclusion Criteria: - Patients they had any signs and symptoms of clinical neuropathy. - Diabetes mellitus - Patients receiving vitamin supplementation including vitamin B1, B6 and B12 - Patients receiving antidepressants, anticoagulants, opioids or anticonvulsants - Patients had a hypersensitivity to curcumin.

Gender: Female

Minimum age: 18 Years

Maximum age: 65 Years

Healthy volunteers: No

Start date: August 30, 2023

Completion date: March 10, 2024

Lead sponsor:
Agency: Ain Shams University
Agency class: Other

Source: Ain Shams University

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05966441